Hypercalcemia remains an adverse prognostic factor  for newly diagnosed multiple myeloma patients in the era of novel anti‐myeloma therapies

Conclusionhypercalcemia remains a poor prognostic feature in the era of novel agents despite the improvement in the outcomes of patients who present with elevated calcium.This article is protected by copyright. All rights reserved.

Source: European Journal of Haematology - July 4, 2017 Category: Hematology Authors: Flora Zagouri, Efstathios Kastritis, Athanasios Zomas, Evangelos Terpos, Eirini Katodritou, Argiris Symeonidis, Sosana Delimpasi, Anastasia Pouli, Theodoros P. Vassilakopoulos, Eurydiki Michalis, Stavroula Giannouli, Zafiris Kartasis, Anna Christoforidou, Tags: Original Article Source Type: research